Synopsis: Akums Drugs is entering FY27 with unusually high revenue visibility. A long-term European CDMO agreement, a Zambia government supply partnership, and a ₹300 crore expansion plan are now converging at the same time. The bigger story is no longer just manufacturing scale; it is whether the company can evolve into a global pharma outsourcing platform.
India’s pharmaceutical outsourcing ecosystem is quietly entering a new phase where scale, export relationships, and manufacturing capacity are becoming more important than domestic branding alone.
One of the country’s largest contract drug manufacturers now appears positioned directly inside that transition. The company manufactures tablets, capsules, syrups, injectables, and other formulations for pharma brands across India while simultaneously expanding into international CDMO and government healthcare supply contracts. What makes FY27 increasingly interesting is not just the recent quarterly numbers. It is the visibility of future revenue already getting locked in.
With a market capitalisation of around ₹8,200 crore, the shares of Akums Drugs and Pharmaceuticals are trading near ₹521 apiece in today’s market session, down 0.02% from their previous day’s close of ₹522 apiece. However, the share price has corrected significantly since its listing in 2024 and is down by 35.25%
The Europe Contract Changes Revenue Visibility
The biggest development is a fixed-price European CDMO agreement running until 2032. Management expects the contract to generate nearly EUR 35 million annually once commercial supplies begin during the next fiscal year. Structurally, this matters because it provides long-duration revenue visibility with relatively stable margins over nearly six years.
In parallel, the company’s Zambia government healthcare partnership is also beginning commercial supplies from Indian manufacturing facilities by the end of Q2 FY27. The Zambia contract itself carries approximately $25 million annual supply potential over two years, implying nearly $50 million of committed business visibility across FY27 and FY28. Together, these contracts significantly strengthen the company’s export-linked manufacturing pipeline at a time when global pharma outsourcing continues shifting toward India.
The FY27 Story Is Actually About Three Businesses
The larger investment case now revolves around three separate businesses moving toward profitability at different speeds. The CDMO business already remains the strongest vertical. Management expects strong double-digit volume growth during H1 FY27, supported by the European contract and African supply expansion.
The branded formulations business, particularly through Akumentis Healthcare, is also expected to deliver double-digit revenue growth driven by new launches and improving field-force productivity. Management indicated that growth should broadly remain in line with the India Pharma Market trends.
The third business, APIs, remains the weakest segment operationally. The segment is facing continuous price pressures due to geopolitical instability, causing raw material bottlenecks. However, management has stated that losses are expected to decline meaningfully during FY27, as they aim to optimize the portfolio, control costs, and improve operational efficiency in this segment, with monthly EBITDA profitability as the near-term target.
This sequencing matters because the profitability recovery is unlikely to happen uniformly. CDMO profitability is already visible, formulations are stabilising, while APIs remain the final operational turnaround piece.
Recent Results Reflect The Transition
Akums Drugs & Pharmaceuticals reported steady FY26 growth driven primarily by its core CDMO business. Q4 FY26 revenue rose 9.7% YoY to ₹1,158 crore, while adjusted EBITDA surged 61.6% to ₹152 crore with margins improving to 13.1%. Adjusted PAT came around ₹81 crore. The company also strengthened its global footprint through Europe commercial supplies, EU GMP certifications, UK MHRA approval, and Zambia plant expansion initiatives.
The company is simultaneously deploying nearly ₹300 crore of FY27 capex, focused heavily on oral solid dosage expansion. That category matters because tablets and capsules remain the largest-volume pharmaceutical formats globally across the US, Europe, Africa, and emerging export markets.
Why The Global Pharma Opportunity Is Expanding
The global generic pharma ecosystem is increasingly becoming volume-driven, especially after recent US healthcare pricing initiatives aimed at reducing medicine costs. That environment structurally benefits Indian manufacturers because India remains one of the world’s lowest-cost large-scale generic drug production hubs.
While the company does not directly sell medicines to US consumers, it manufactures products for several Indian pharmaceutical companies that ultimately participate in global generic markets. As outsourcing volumes increase globally, India’s large-scale CDMO players could become some of the biggest indirect beneficiaries.
Risks Still Remain
Despite the improving outlook, the business still carries meaningful risks. The API segment remains loss-making. Export businesses also remain vulnerable to regulatory inspections, pricing pressure, and customer concentration risks.
Pharmaceutical manufacturing is heavily execution-dependent, particularly in export markets where compliance standards remain extremely strict. The company is also entering a phase where large-scale capacity additions need to translate into sustained utilisation growth. If volume ramp-up slows, return ratios could remain under pressure despite higher revenue visibility.
Market Takeaway
The company increasingly looks less like a traditional domestic pharma manufacturer and more like a scaled pharmaceutical outsourcing platform entering its next growth cycle.
The European contract until 2032, Zambia healthcare supplies, ₹300 crore capacity expansion, and improving CDMO momentum collectively create a far stronger revenue visibility profile than most investors currently appear to be pricing in.
The bigger question now is whether management can successfully execute the next transition, from being India’s largest contract manufacturer to becoming a globally relevant pharmaceutical outsourcing platform with stronger export positioning and higher-margin businesses over time.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
